Oct 14, 2022
Oct 30, 2023
The natural history of mantle cell lymphoma (MCL) is a repeated pattern of remission and relapse; after a few relapses, patients have a very small chance of responding to any therapy. Considerable progress has been made over the last decade as the treatment paradigm has shifted from traditional chemoimmunotherapy toward targeted and cell-based therapies in both the frontline and relapsed/refractory (R/R) settings. However, selecting the best treatment is often complicated, involving multiple patient factors, and there is no established standard of care.
During Transitioning from Chemoimmunotherapy to More Targeted Approaches in MCL, experts discuss using prognostic tools to plan treatment for individuals with MCL and targetable mutations, integrating emerging data and guidelines recommendations for front-line treatment, potential benefits and risks of chemotherapy-free targeted options, planning safe and effective use of novel therapies and combinations in the second- and third-line settings and for R/R MCL, and eradicating health inequities and closing the survival gap.
This taped Satellite Symposium was derived from the Society of Hematologic Oncology 2022 Annual Meeting.
Division Head ad Interim, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
John M O'Quimm Endowed Chair in Cancer Research
MD Anderson Cancer Center
Christopher R. Flowers, MD, MS joined The University of Texas MD Anderson Cancer Center in August 2019 as Chair of the Department of Lymphoma/Myeloma and was appointed Division Head ad interim of Cancer Medicine in August 2020. Through the COVID-19 pandemic, Dr. Flowers’ leadership contributed to the institution’s recovery in patient volume while maintaining accelerated safety measures. Prior to MD Anderson, he was professor of Hematology and Oncology with a joint appointment in Biomedical Informatics at Emory University School of Medicine in Atlanta. During his tenure there, he served the Winship Cancer Institute as director of the Lymphoma Program for 13 years and as scientific director of Research Informatics for four years. An internationally recognized expert in lymphoma clinical care, epidemiology and outcomes research, Dr. Flowers is an innovator who has a passion for facilitating new drug development. He is an active clinician who conducts clinical research involving cancer outcomes, cancer informatics, and phase 1/2 trials, focusing on the clinical development of novel therapeutics for B-cell lymphomas. His broader research interests include patient-oriented research in lymphoma and computer microsimulation models and cost-effectiveness analyses aimed at developing strategies to individualize care for cancer patients and improve systems of care. His work has resulted in >300 peer-reviewed publications. He has received peer-reviewed funding from foundations and the NIH including leading multi-institutional team science grants such as the Lymphoma Epidemiology of Outcomes (LEO) Cohort Study. The largest prospective study of lymphoma patients in the US.
Dr. Flowers has served in many capacities for national professional societies and was elected to membership in the American Society of Clinical Investigation. In 2018, he was named a Fellow of the American Society of Clinical Oncology (ASCO), and served as chair of both the ASCO guidelines on management of febrile neutropenia and ASCO Health Disparities Committee. In the American Society of Hematology, Dr. Flowers has served as educational co-chair for the annual meeting, a longstanding faculty member and co-director of the Clinical Research Training Institute, and Chair of the Committee on Promoting Diversity. In each of these roles, he has committed to training and developing new leaders in hematology and oncology clinical research.
Professor of Clinical Medicine
Division of Hematology & Medical Oncology
Weill Cornell Medicine,
New York, NY
Dr. Ruan is a Professor of Clinical Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medical College and New York Presbyterian Hospital in New York City. She leads clinical trials in mantle cell lymphoma and peripheral T-cell lymphoma at Weill Cornell. Dr. Ruan received comprehensive training in medicine and immunology leading to combined MD-PhD degrees from the Tri-Institutional Medical Scientist Training Program of Cornell University, the Rockefeller University and Sloan-Kettering Cancer Institute. She completed residency in internal medicine and fellowship in hematology/oncology at the Stanford University Medical Center and New York Presbyterian Hospital before joining faculty at Weill Cornell Medical College. Dr. Ruan’s research expertise focuses on development of novel therapeutics targeting tumor microenvironment and tumor immunology in both B-cell and T-cell non-Hodgkin lymphomas. She has served as an annual meeting abstract reviewer/coordinating reviewer and Highlights of ASH speaker for the American Society of Hematology. She chaired the Aggressive Lymphoma Education Session at ASH in 2019. She serves on the lymphoma committee of the cooperative intergroup ALLIANCE, and the Lymphoma Research Foundation MCL Research Consortium. Her research efforts have been recognized and supported by research funding from the Lymphoma Research Foundation, the ASCO Foundation, the Leukemia and Lymphoma Society, and the National Institute of Health. Dr. Ruan has published articles in leading research journals including the Journal of Biological Chemistry, Journal of Experimental Medicine, PNAS, Blood, Annals of Oncology, Cancer, the Journal of Clinical Oncology and the New England Journal of Medicine.
This CE activity is intended for hematologic oncology clinicians, nurses, and pharmacists who provide care for individuals with mantle cell lymphoma (MCL).
After completing this CE activity, the participant should be better able to:
ACCREDITATION, SUPPORT AND CREDIT
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
The European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMS-EACCME®) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)™ into European CME credit (ECMEC®) should contact the UEMS (www.uems.eu).
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hour (0.10 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-111-H01-P
Type of Activity: Knowledge
This CE activity is supported by educational grants from AstraZeneca, Pharmacyclics, LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Lilly.
DISCLOSURE & CONFLICT OF INTEREST POLICY
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Christopher R. Flowers, MD, MS
Division Head ad Interim, Division of Cancer Medicine
Department Chair, Department of Lymphoma/Myeloma, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Advisory Board/Consultant: AbbVie, Bayer, BeiGene, Celgene, Denovo Biopharma, Epizyme, Genentech/Roche, Genmab, Gilead, Karyopharm, Pharmacyclics/Janssen, SeaGen, and Spectrum.
Research Grant: 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD Serono, Gilead, Genentech/Roche, Guardant, Iovance, Janssen Pharmaceutical, Kite Pharma, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm, Burroughs Wellcome Fund, Eastern Cooperative Oncology Group, National Cancer Institute, and Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research.
Jia Ruan, MD, PhD
Professor of Clinical Medicine, Lymphoma Program
Division of Hematology & Medical Oncology
Weill Cornell Medicine
New York, NY
Advisory Board/Consultant: AstraZeneca, Daiichi Sankyo, Kite Pharma, and Secura Bio.
Research Grant: AstraZeneca, Celgene/Bristol Myers Squibb, Daiichi Sankyo, and Genentech
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: Seagen.
All of the relevant financial relationships of individuals for this activity have been mitigated.
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc., do not have any relevant financial relationship(s) to disclose with ineligible companies
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Mary Vu via email at firstname.lastname@example.org
For Physicians, if requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
ABOUT THIS ACTIVITY
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2022 Medical Learning Institute, Inc. All Rights Reserved.